


SCH 546738

Cat. No.:	HY-10017		
CAS No.:	906805-42-3		
Molecular Formula:	C ₂₃ H ₃₁ Cl ₂ N ₇ O		
Molecular Weight:	492.44		
Target:	CXCR		
Pathway:	GPCR/G Protein; Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 4.5 mg/mL (9.14 mM; Need ultrasonic)
H₂O : < 0.1 mg/mL (insoluble)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.0307 mL	10.1535 mL	20.3070 mL
5 mM	0.4061 mL	2.0307 mL	4.0614 mL
10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: corn oil
Solubility: 1 mg/mL (2.03 mM); Suspended solution; Need ultrasonic and warming

BIOLOGICAL ACTIVITY

Description

SCH 546738 is a potent, orally active and non-competitive CXCR3 antagonist, the affinity constant (K_i) of SCH 546738 binding to human CXCR3 receptor is determined to be 0.4 nM in multiple experiments.

IC₅₀ & Target

Human CXCR3
0.4 nM (K_i)

In Vitro

The affinity of SCH 546738 binding to human CXCR3 receptor is determined by competition binding analysis using ³⁵S radiolabeled SCH 535390 (a sulfonamide analog of the CXCR3 compound series with a K_d of 0.6 nM) as a competitive tracer. In addition, SCH 546738 displaces radiolabeled CXCL10 and CXCL11 from human CXCR3 with IC₅₀ ranging from 0.8 to 2.2 nM in a non-competitive manner. SCH 546738 potently and specifically inhibits CXCR3-mediated chemotaxis in human activated T cells with IC₉₀ about 10 nM. Competition of human CXCL10 and CXCL11 binding to human CXCR3 by SCH 546738

is determined at various concentrations of [¹²⁵I]hCXCL10 and [¹²⁵I]hCXCL11 around the K_d (50-100 pM) for the receptor. The IC₅₀ of SCH 546738 is constant (~1 or 2 nM) and independent of the input concentrations of either [¹²⁵I]hCXCL10 (25-500 pM) or [¹²⁵I]hCXCL11 (12.5-250 pM), respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SCH 546738 has strong cross-species activities with IC₅₀ of 1.3 nM, 6.4 nM, 5.9 nM and 4.2 nM in inhibiting the binding of [¹²⁵I]hCXCL10 to CXCR3 of monkey, dog, mouse and rat origin, respectively. SCH 546738 is a selective and potent CXCR3 antagonist with a good PK for in vivo studies. In addition, SCH 546738 has a favourable pharmacokinetic profile in rodents, the plasma concentrations of SCH 546738 in Lewis rat and C57BL/6 mouse over 24 hr post-dose. The AUC (0-24 hr) is 7.7 μM.hr in Lewis rat 10 mg/kg (mpk) and is 12.6 μM.hr in C57BL/6 mouse 30 mpk^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[1]

The preparation of human activated T cells is performed. Human peripheral blood lymphocytes are prepared, depleted of monocytes, and stimulated for 2 days with 1 μg/mL PHA and 100 U/mL IL-2 in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 2 mM L-Glutamine, 1% non-essential amino acids and 2 mM HEPES. Following stimulation, peripheral blood lymphocytes are cultured in above media containing 5% conditioned media for up to 15 days. Human activated T cell chemotaxis assays are performed using 96-well ChemoTx microplates with a 3 μm filter. Activated T cells are washed with RPMI medium twice, and then resuspended in the medium containing 20% FBS. 1.25×10⁵ cells/reaction are mixed with indicated concentrations of SCH 546738 (1, 10 or 100 nM) and placed on the filter. SCH 546738 and chemokines are mixed and placed in the bottom well of the ChemoTx system. After 2.5 hours incubation at 37°C/5% CO₂, the cells are scraped off and the plate system is centrifuged for 5 minutes at 1000 RPM. The filter screen is then removed and the ChemoTx plate is inverted into a 96 well plate with a funnel plate. The plate system is centrifuged for 5 minutes at 1000 RPM. The volume in the wells is brought to 100 μL with assay buffer and the plates are rested for approximately 15 minutes at room temperature. The number of migrated cells is measured using the Cell Titer Glo Luminescent Assay. Chemotaxis is expressed as a chemotactic index, which is a ratio versus the one without chemokines^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[1]

Mice^[1]

Female C57BL/6 mice are used. For immunization, 150 μg MOG35-55 peptide prepared by Princeton Biomolecules and 300 μg killed Mycobacterium tuberculosis are mixed in CFA and injected s.c. in two 50-μL injections over the flanks on day 1. Also, 200 ng of pertussis toxin is injected i.v. on days 0 and 2. SCH 546738 is administered orally 30 mpk in C57BL/6 mice twice daily. Dosing with SCH 546738 started at day 0, 24 h prior to MOG35-55 immunization (day 1). Mice are monitored daily and assessed for clinical signs of disease in a blinded fashion according to the following criteria: 0, no signs of disease; 1, tail paralysis; 2, limp tail and hind limb weakness; 3, hind limb paralysis; 4, hind limb plus forelimb paralysis; and 5, moribund or dead. Cumulative clinical scores are calculated by adding daily scores from the day of immunization until the end of the experiment. Mean clinical scores at separate days and mean maximal scores are calculated by adding the scores of individual mice and dividing with the number of mice in each group, including mice not developing signs of EAE.

Rats^[1]

Male Lewis rats challenged by injection of 50 μL (30 mg) of a guinea pig spinal cord homogenate in complete Freund's adjuvant (CFA) into one footpad. SCH 546738 or 0.4% methylcellulose (vehicle) is orally administered at the indicated dose (0.2 mL) twice a day, starting on the day before transplantation until the day of graft rejection. SCH 546738 is administered orally at 10 mg/kg (mpk) in Lewis rats. To test whether SCH 546738 enhances the effect of conventional immunosuppressive reagent, the recipients are received treatment with subtherapeutic dose of CsA for one week combined with treatment with SCH 546738. Graft survival is analyzed using the log-rank test. The parametric data are analyzed by Student t test (2-tailed) using GraphPad InStat version.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Hepatol. 2016 Jan;64(1):160-70.
- Nat Commun. 2017 Nov 17;8(1):1571.
- J Allergy Clin Immunol. 2016 Jul;138(1):114-122.e4.
- Cancer Immunol Res. 2015 Aug;3(8):864-70.
- Theranostics. 2017 Sep 26;7(17):4192-4203.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Jenh CH, et al. A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection. BMC Immunol. 2012 Jan 10;13:2.
- [2]. Zhang X, et al. CXC chemokine receptor 3 promotes steatohepatitis in mice through mediating inflammatory cytokines, macrophages and autophagy. J Hepatol. 2016 Jan;64(1):160-70.
- [3]. Yue C, et al. STAT3 in CD8⁺ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis. Cancer Immunol Res. 2015 Aug;3(8):864-870.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA